Shopping Cart
Remove All
Your shopping cart is currently empty
Cadonilimab (Synonyms: BTG502)
Catalog No. T76716 Copy Product Info
Purity: 95%
🥰Excellent
Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.
Cadonilimab
Copy Product Info🥰Excellent
Catalog No. T76716
Synonyms BTG502
Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.
Cadonilimab
Cas No. 2394841-59-7
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $373 | - | In Stock | |
| 5 mg | $1,200 | - | In Stock | |
| 10 mg | $1,990 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma. |
| In vivo | Methods: The NCG mouse subcutaneous xenograft model (MGC803 cell line) was employed, with cadonilimab administered via intraperitoneal injection. The dosing regimen was as follows: the first three doses at 1 mg/kg (initiated on day 4 post-grouping, twice weekly for three consecutive weeks), followed by six doses at 5 mg/kg (twice weekly for six consecutive weeks). Result: Cadonilimab demonstrated significant anti-tumor efficacy when combined with chemotherapy, but exhibited limited effectiveness when used alone.[1] |
| Synonyms | BTG502 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CTLA4 & PDCD1 |
| Molecular Weight | 198.64 kDa |
| Cas No. | 2394841-59-7 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Cadonilimab | purchase Cadonilimab | Cadonilimab cost | order Cadonilimab | Cadonilimab in vivo | Cadonilimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.